Travere Therapeutics Ownership | Who Owns Travere Therapeutics?

Overview Forecast RevenueFinancials Chart Transcripts

Travere Therapeutics Ownership Summary

Travere Therapeutics is owned by 106.26% institutional investors, 0.65% insiders. Blackrock is the largest institutional shareholder, holding 9.86% of TVTX shares. Delaware Small Cap Core I is the top mutual fund, with 4.42% of its assets in Travere Therapeutics shares.

TVTX Ownership Benchmark

Type	Name	% Inst	% Insiders	% Retail
Stock	Travere Therapeutics	106.26%	0.65%	-6.92%
Sector	Healthcare Stocks	49.73%	8.84%	41.43%
Industry	Biotech Stocks	47.04%	8.74%	44.21%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

Holder	Shares	% Holding	Value
Blackrock	7.64M	9.86%	$62.84M
Armistice capital	7.50M	9.68%	$61.65M
Deep track capital, lp	7.37M	9.51%	$60.58M
Vanguard group	6.62M	8.54%	$54.41M
Rock springs capital management lp	4.48M	5.78%	$36.84M
Macquarie group	4.37M	5.64%	$35.90M
State street	3.51M	4.53%	$28.86M
Morgan stanley	3.49M	4.50%	$28.69M
Millennium management	2.95M	3.81%	$24.24M
Assenagon asset management	2.21M	2.86%	$18.20M

Top Institutional Shareholders by % of Total Assets

Holder	Shares	% Assets	Value
Finepoint capital lp	1.78M	4.15%	$14.60M
Deep track capital, lp	7.37M	1.81%	$60.58M
Kynam capital management, lp	2.02M	1.28%	$16.62M
Rock springs capital management lp	4.48M	1.11%	$36.84M
Parkman healthcare partners	969.89K	1.07%	$7.97M
Birchview capital, lp	122.00K	0.93%	$1.00M
Knott david m jr	265.97K	0.87%	$2.19M
Armistice capital	7.50M	0.78%	$61.65M
Highvista strategies	219.42K	0.66%	$1.80M
Eversept partners, lp	1.09M	0.61%	$8.97M

Top Buyers

Holder	Shares	% Assets	Change
Assenagon asset management	2.21M	0.04%	2.00M
Woodline partners lp	1.28M	0.10%	1.28M
Rock springs capital management lp	4.48M	1.11%	1.06M
Jacobs levy equity management	1.89M	0.06%	765.16K
Millennium management	2.95M	0.01%	747.41K

Top Sellers

Holder	Shares	% Assets	Change
State street	3.51M	0.00%	-3.10M
Deutsche bank ag\	946.60K	0.00%	-1.45M
Pictet asset management sa	977.95K	0.01%	-1.26M
Renaissance	2.20M	0.03%	-658.20K
Citigroup	44.95K	0.00%	-462.08K

New Positions

Holder	Shares	% Assets	Change	Value
Trexquant investment lp	174.49K	0.02%	174.49K	$1.43M
Norges bank	71.00K	0.00%	71.00K	$583.62K
Hudson bay capital management lp	44.56K	0.00%	44.56K	$366.29K
Mirae asset global etfs	44.28K	0.00%	44.28K	$364.43K
Engineers gate manager lp	41.76K	0.01%	41.76K	$343.27K

Sold Out

Holder	Change
Toronto dominion bank	-3.00
Nelson, van denburg & campbell wealth management group	-14.00
Global retirement partners	-19.00
Innealta capital	-28.00
Northwestern mutual wealth management	-39.00

Institutional Ownership Trends

Date	Holdings	Change %	Shares	Change %	Ownership	Change %	Increased Position	Change %	Decreased Position	Change %
Sep 30, 2024	185	5.11%	82,651,760	-6.09%	106	0.82%	96	-6.80%	54	14.89%
Jun 30, 2024	176	-1.68%	88,008,878	0.38%	113	0.88%	103	10.75%	47	-7.84%
Mar 31, 2024	179	2.29%	87,677,449	2.46%	113	0.91%	93	3.33%	51	-5.56%
Dec 31, 2023	175	-7.41%	85,573,713	3.91%	111	0.96%	90	-15.09%	54	8.00%
Sep 30, 2023	189	8.62%	82,354,299	-0.97%	107	0.90%	106	-4.50%	50	21.95%

Top Mutual Funds Shareholders

Holder	Shares	% Holding	Change
Delaware Small Cap Core I	3.45M	4.42%	-21.39K
Vanguard Total Stock Mkt Idx Inv	2.51M	3.21%	3.93K
Aviva Investors GlConvtAbsRet I USD Acc	2.20M	2.88%	-229.35K
iShares Russell 2000 ETF	1.90M	2.43%	-4.27K
HBM Healthcare Investments AG Ord	1.50M	1.96%	-
Pictet Biopharmaceutical Mother	1.09M	1.43%	5.28K
Vanguard Institutional Extnd Mkt Idx Tr	1.04M	1.33%	-14.67K
SPDR® S&P Biotech ETF	1.01M	1.30%	11.19K
Vanguard Strategic Equity Inv	972.18K	1.25%	94.33K
Vanguard Explorer Inv	967.61K	1.24%	-

Recent Insider Transactions

Date	Name	Role	Activity	Value
Nov 25, 2024	Calvin Sandra	SVP, CHIEF ACCOUNTING OFFICER	Sell	$221.26K
Oct 04, 2024	LYONS GARY A	-	Sell	$303.87K
Oct 04, 2024	LYONS GARY A	-	Sell	$285.23K
Sep 30, 2024	Meckler Jeffrey A	-	Sell	$562.32K
Sep 10, 2024	Inrig Jula	CHIEF MEDICAL OFFICER	Sell	$8.88K

Insider Transactions Trends

Date	Buy	Sell
2024 Q4	-	3
2024 Q3	-	9
2024 Q2	-	1
2024 Q1	-	18
2023 Q4	-	1

TVTX Ownership FAQ

Who Owns Travere Therapeutics?

Travere Therapeutics shareholders are primarily institutional investors at 106.26%, followed by 0.65% insiders and -6.91% retail investors. The average institutional ownership in Travere Therapeutics's industry, Biotech Stocks , is 47.04%, which Travere Therapeutics exceeds.

Who owns the most shares of Travere Therapeutics?

Travere Therapeutics’s largest shareholders are Blackrock (7.64M shares, 9.86%), Armistice capital (7.5M shares, 9.68%), and Deep track capital, lp (7.37M shares, 9.51%). Together, they hold 29.05% of Travere Therapeutics’s total shares outstanding.

Does Blackrock own Travere Therapeutics?

Yes, BlackRock owns 9.86% of Travere Therapeutics, totaling 7.64M shares as of Jun 2024. This represents 0.00% of BlackRock's total assets, with a market value of 62.84M$. In the last quarter, BlackRock decreased its holdings by -152K shares, a -1.95% change.

Who is Travere Therapeutics’s biggest shareholder by percentage of total assets invested?

Finepoint capital lp is Travere Therapeutics’s biggest shareholder by percentage of total assets invested, with 4.15% of its assets in 1.78M Travere Therapeutics shares, valued at 14.6M$.

Who is the top mutual fund holder of Travere Therapeutics shares?

Delaware Small Cap Core I is the top mutual fund holder of Travere Therapeutics shares, with 4.42% of its total shares outstanding invested in 3.45M Travere Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis

Discover trending investment themes
Find your next best investment
Research stocks using tools